Moderna Vaccine (mRNA-1273)

Status
To Patients
Condition
COVID-19
Intervention Type
Intramuscular (IM) Injection
Funder Type
Industry

Drug Details

mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2. 

More Information

On December 18, 2020, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.

Moderna COVID-19 Vaccine

This drug has no clinical trials actively recruiting patients at this time.

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >